Filter on [PROGRAMME PRIORITY=3HP.1.1.4.]

3rd Health Programme (2014-2020)
Conferences organized under the Croatian Presidency in 2020: (1) Organs donation and transplantation and (2) a conference e-Health Week [HRPRES]
Croatian Ministry of Health is organising two important events during the Croatian presidency of the Council of the EU in 2020: High level conference on organ donation and transplantation and e-Health...
Croatian Ministry of Health is organising two important events during the Croatian presidency of the Council of the EU in 2020: High level conference on organ donation and transplantation and e-Health Week.
The aim of the high level conference on organ donation and transplantation conference is to engage EU health ministers and national policymakers to:
- provide political support and strong commitment to further developing and strengthening the implementation of successful organ donation and transplantation programmes,
- exchange experience and discuss best approaches aimed at increasing the availability of organs for transplantation
- identify new challenges and priorities for joint action in this area of public health and agree on directions and models for further development
E-Health Week plans to place particular emphasis on taking measures related to actionable health data and secondary use of data by creating the space for European policy making and enabling and implementing uniform European health data standards for interoperability, security, practices for data collection, sharing and ethical processing.


Start date: 01/01/2020 - End date: 31/07/2020

Call: Presidency conference grants 2019 under the AWP 2019 of 3HP
Topic: 4.5 Actions required by, or contributing to, the implementation of Union legislation in the fields of human tissues and cells, blood, human organs, medical devices, medicinal produc...
Topic: 4.5 Actions required by, or contributing to, the implementation of Union legislation in the fields of human tissues and cells, blood, human organs, medical devices, medicinal products, and patients' rights in cross-border healthcare, while fully respecting the competences and ethical choices of Member States in those fields. Such action may include activities aimed at facilitating the implementation, application, monitoring and review of that legislation.
3rd Health Programme (2014-2020)
Health Alliance for Prudent Prescription and Yield of Antibiotics in a Patient-centered Perspective [HAPPY PATIENT]
The HAPPY PATIENT project aims at reducing the inappropriate use and dispensing of antibiotics in the most common community-acquired infections (i.e., respiratory tract infections, urinary tract infec...
The HAPPY PATIENT project aims at reducing the inappropriate use and dispensing of antibiotics in the most common community-acquired infections (i.e., respiratory tract infections, urinary tract infections, dental infections) with a multifaceted intervention in health care facilities as suggested in point 4.2 of the EU guidelines for the prudent use of antimicrobials in human health. The multifaceted intervention will be carried out in five countries with a diverse pattern of antibiotic consumption: ES, FR, LT, PL and GR.
We will follow a model which both promotes both stakeholder stewardship and is patient-centred. The critical focus will be on the most important interaction in determining usage of antibiotics: contact between patients and health professionals at different levels of the Health Care System. Hence, activities of HAPPY PATIENT will target patients, primary care professionals (general practitioners, nurses, and dentists), secondary care (out-of-hours services), nursing homes and community pharmacists.
We will follow the Audit Project Odense (APO) methodology developed in FP6 HAPPY AUDIT project. APO consists of an audit-based registration to perform a context analysis before the implementation of the multifaceted intervention, and then to perform an assessment of changes after the implementation of the multifaceted intervention. Based on the Normalization Process Theory for changing behaviour, the multifaceted intervention will include: a) peer feedback with reflexion and discussion, b) enhancement of communication skills in order to improve the communication process between the health professionals and the patients, c) patient information leaflets and posters, d) country-tailored information on antibiotic usage(incl. the “antibiotic foot-print”).
HAPPY PATIENT expects to reduce the inappropriate prescription of antibiotics by 40%. Its key outputs will be both scalable and capable of implementation throughout the diverse health systems in the EU.

Start date: 01/01/2021 - End date: 31/12/2023
Call: Call for Proposals for Projects 2019
Topic: 4.4 In line with the Action Plan against the rising threats from antimicrobial resistance, improve the prudent use of antimicrobial agents and reduce the practices that increase ant...
Topic: 4.4 In line with the Action Plan against the rising threats from antimicrobial resistance, improve the prudent use of antimicrobial agents and reduce the practices that increase antimicrobial resistance, particularly in hospitals; promote effective prevention and hygiene measures to prevent and control infections; reduce the burden of resistant infections and healthcare-associated infections and secure the availability of effective antimicrobials.
3rd Health Programme (2014-2020)
Unified European Registry for Inherited Metabolic Disorders [U-IMD]
More than 700 inherited metabolic diseases (IMDs) have been identified so far. Each single IMD is a rare condition, but collectively IMDs are affecting at least one in 500 newborns. Clinical presentat...
More than 700 inherited metabolic diseases (IMDs) have been identified so far. Each single IMD is a rare condition, but collectively IMDs are affecting at least one in 500 newborns. Clinical presentation of IMDs is wide-ranging from involvement of single organ systems to multi-systemic disease, confronting patients with significant and often severe health problems resulting in high morbidity, reduced life expectancy, and low quality of life.
For a limited number of IMDs networking activities already exist on a European or international level. The E-IMD, E-HOD and iNTD family of IMD registries has a relevant impact on improving the health of patients with IMDs and facilitates post-authorisation safety studies (PASS) for orphan drugs. However existing registries still do exclude a significant portion of IMDs and do not fulfill all core recommendations made by the European Union Committee of Experts on Rare Diseases (EUCERD). The recent inception of the European Reference Network for Hereditary Metabolic Diseases (MetabERN) lays the foundation for the development of an overarching European IT platform for IMD registries.
The project consists of 3 components: (1) a novel registry platform for all known IMDs, (2) an upgrade of existing IMD registries and (3) a collaboration with the European Rare Kidney Disease Reference Network (ERKNet). The new Unified European Registry for Inherited Metabolic Diseases (U-IMD) will encompass all known IMDs, fully implementing EUCERD recommendations. Data modules developed for U-IMD will be integrated in the existing IMD registries, with the iNTD registry as pilot, thus reaching interoperability of patient records. MetabERN and ERKNet will develop a common standard for minimal core data sets.
The U-IMD registry will follow an open multiple stakeholder approach, explicitly seeking collaborations with national and EU level health authorities, other scientific networks and consortia, patient and parent organizations and industry.

Start date: 01/02/2018 - End date: 31/07/2021

Call: Rare diseases - support for New Registries
Topic: 4.2 Support Member States, patient organisations and stakeholders by coordinated action at Union level in order to effectively help patients affected by rare diseases. This includes...
Topic: 4.2 Support Member States, patient organisations and stakeholders by coordinated action at Union level in order to effectively help patients affected by rare diseases. This includes the creation of reference networks (in compliance with point 4.1), Union wide information databases and registries for rare diseases based on common criteria.